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Introduction. Basal cell carcinoma (BCC) is a locally invasive malignant epidermal tumour. Incidence is increasing by 10% per year;
incidence of metastases is minimal, but relapses are frequent (40%–50%). The complete excision of the BCC allows reduction of
relapse.Materials and Methods. The study cohort consists of 1123 patients underwent surgery for basal cell carcinoma between 1999
and 2009. Patient and tumor characteristics recorded are: age; gender; localization (head and neck, trunk, and upper and lower
extremities), tumor size, excisional margins adopted, and relapses. Results. The study considered a group of 1123 patients affected
by basal cell carcinoma. Relapses occurred in 30 cases (2,67%), 27 out of 30 relapses occurred in noble areas, where peripheral
margin was <3mm. Incompletely excised basal cell carcinoma occurred in 21 patients (1,87%) and were treated with an additional
excision. Discussion. Although guidelines indicate 3mm peripheral margin of excision in BCC <2 cm, in our experience, a margin
of less than 5mm results in a high risk of incomplete excisions.
1. Introduction
Basal-cell carcinoma (BCC) is a slow-growing, locally inva-
sive malignant epidermal skin tumour. The lesion infiltrates
tissues in a three-dimensional fashion [1] through the
irregular growth of subclinical finger-like outgrowths which
remain contiguous with the main tumour mass [2, 3].
Metastasis is extremely rare [4, 5], and morbidity results
from local tissue invasion and destruction, particularly on
the face, head, and neck.
Incidence of basal-cell carcinoma alone is increasing by
10% per year worldwide, suggesting that prevalence of this
tumor will soon equal that of all other cancers combined [6].
Although the incidence of metastases is minimal, relapses
are, in the other hand, very frequent; indeed, an estimated
40%–50% of patients with a primary carcinoma will develop
at least one or more further basal-cell carcinomas within
5 years [7]. According to a meta-analysis of 16,066 cases,
recurrence rates for 5mm, 4mm, 3mm, and 2mm surgical
margins were 0.39, 1.62, 2.56, and 3.96 percent, respectively
[8]. Mohs technique recurrence rate is 4,5% in five years [9].
A wide range of different treatments has been described
for the management of BCC [10]. Some techniques, as
cryosurgery, curettage, RT, photodynamic therapy do not
allow histological confirmation of tumour clearance. Differ-
ently surgical excision with either intraoperative or postoper-
ative histological assessment of the surgical margins is widely
used to treat BCC and is generally considered to have the
lowest overall failure rate in BCC treatment [11].
The complete excision of the BCC allows disease control
and reduction of relapse considered and is an appropriate
surgical treatment which must focalize on the peripheral
margin.
2. Materials and Methods
The study cohort consists of 1123 patients who underwent
surgery for basal-cell carcinoma between 1999 and 2009. All
the cases were treated in Department of Plastic and Recon-
structive surgery of Policlinico Umberto I. Including criteria
are: positivity to BCC at histological analysis and follown up
period longer than 1 year. Patients with inadequate follown
up, defined as <1 year or <2 visits per year were excluded
from the analysis.
The excision of the neoplasm was performed by the
same plastic surgeon as well as histological evaluation
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was performed by the same pathologist during the study
period. Specimens were histologically evaluated to determine
the predominant histologic subtype (superficial, nodular,
infiltrative BCC or mixed pattern consisting of both nodular
and infiltrative BCC subtypes).
Patients’ followup was made by a plastic surgeon or
by a dermatologist related to Dermatology, Plastic, and
Reconstructive Surgery Department.
The following patient and tumor characteristics were
recorded: age, gender, anatomic location (head and neck,
trunk, and upper and lower extremities), tumor size, exci-
sional margins adopted, and relapses.
3. Results
The study considered a group of 1123 patients affected by
basal-cell carcinoma. Average age was 64,5 years old. A
relevant difference came out between two genders. 764 Males
(68%) were affected in comparison with only 359 females
(32%). Concerning areas affected, first was cervicofacial area
with a prevalence of 652 cases (58%), second trunk 256 cases
(23,5%), third lower limbs 97 cases (8,9%), fourth upper
limbs 71 (6%), and other areas 47 cases (3,6%).
Average diameter of lesions was 12.2mm; the biggest
lesion measured 5.3 cm, the smallest 0.2 cm. Margins taken
were 3 to 5mm on cervico-facial area, 2-3mm on noble
areas as lips, ears, and eyelid and 5 to 10mm on other areas.
An additional excision of 3mm from the scar’s margin was
performed in incompletely excised neoformations.
Relapses occurred in 30 cases (2.67%); 27 (90%) out of
the 30 relapses were located in noble areas in which the
initial peripheral margin of excision was <3mm. Two further
relapses were located at the neck and one at the trunk.
A relation between relapses and histological subtype was
evident. In effect, morphoeic-infiltrative subtype accounted
for 63% (18 cases) of relapsed forms, micronodular subtype,
superficial subtype, while nodular subtype accounted for
31.5% (9 cases), 7% (2 cases), and 3,5% (1 case), respec-
tively. Incompletely excised basal cell carcinoma occurred
in 21 patients (1.87%) and were treated with an additional
excision. No metastases were documented.
4. Discussion
Optimal management of basal-cell carcinoma is increasingly
relevant in an aging population in which BCC is the fifth
most costly cancer [12].
Because of great increase in incidence of this cancer, a
detailed analysis on what are risk factors and how best to
manage BCC was carried out by many authors [7, 13–15].
The main risk factor is sun exposure, because UVB
radiation causes direct damage to DNA and RNA by inducing
covalent bond formation between adjacent pyrimidines,
leading to generation of mutagenic photoproducts such as
cyclopyrimidine dimers (TT) and pyrimidine-pyrimidine
(6–4) adducts [14]. UVA is less mutagenic than is UVB, and
causes indirect DNA damage via a photo-oxidative stress-
mediated mechanism, resulting in formation of reactive
oxygen species, which interact with lipids, proteins, and
DNA to generate intermediates that combine with DNA to
form adducts [16]. Several complex DNA repair systems are
needed to prevent the harmful effects of these premutagenic
adducts [17].
As a matter of fact, a mutation in the genes coding
for repair proteins are involved in numerous syndromes
characterized by the proliferation of basal-cell carcinoma.
An example of these syndromes are Gorling-Goltz one,
produced due to amutation in patched gene (PTCH), located
in the 9q22.3 chromosome, with loss of heterozygosity. This
gene is involved in a great variety of processes such as the
embryogenesis, homeostasis maintenance in the old tissues,
tissue repairing during the persistent chronic inflammation
and carcinogenesis [18, 19].
Although the understanding of BCC pathogenesis is
greatly improved, incidence of the disease is steadily increas-
ing, and the surgeon’s task is to assess the best BCC
management.
Factors indicating poor prognosis in BCC are a size
>5 cm (giant), morphemic clinical subtype, tumour depth,
infiltrative and micronodular histological subtype, and
recurrent lesions. In addition, systemic alteration can be
connected to a worse prognosis such as immunosuppression
and distant metastasis. Another feature of bad prognosis
recurrent lesions hence is incomplete excision should be
considered a poor prognostic factor, since patients with an
inadequately excised lesion present a higher risk of local
recurrence [20–23]. An assessment of last two points leads
to the assumption that a complete excisional treatment
improves the prognosis of the patient by limiting relapses.
Although numerous different treatments have been
described for the management of BCC, surgical excision is
a highly effective treatment for primary lesions [24, 25].
According to our data, recurrence rate is <2% after a
complete excision. In order to perform the best surgical
treatment, the size of the peripheral and deep surgical
margins should correlate with the likelihood that subclinical
tumour extensions exist. According Griffiths et al. [26], deep
margin clearance is in the range between 0,1 and 9.9mm.
Generally, as this will depend upon the local anatomy,
excision through subcutaneous fat is advisable.
According to the guidelines [27], excision of small
(<20mm) well-defined lesions with a 3mm peripheral sur-
gical margin will clear the tumour in 85% of cases. A 4-5mm
peripheral margin will increase the peripheral clearance rate
to approximately 95%, indicating that approximately 5% of
small, well-defined BCCs extend over 4mm beyond their
apparent clinical margins.
Although guidelines indicate as 3mm peripheral margin
of excision in BCC <2 cm, in our experience, a margin of
less than 5mm results in a high risk of incomplete excisions.
Almost all the recurrences in our series (90%) occurred in
noble areas, in which the peripheral margin was minimal.
This indicates clearly that a minimum margin of excision
(<3mm) increases considerably the risk of relapse, even if
the histology shows complete excision of lesion.
Similar data are reported by Griffiths et al. who stated
that [26] only 65% of BCC excisions had peripheral
clearance margins in the range of 0.1–4.9mm. According
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Figure 1: (a) and (b) Pre- and postintervention on zygomatic region.
(a) (b)
Figure 2: (a) and (b) Pre- and postoperative on forehead.
to Madan et al. [7], a 4-5mm surgical margin ensures
peripheral clearance in roughly 95% of well-defined small
basal-cell carcinomas.
So no way a margin of 3mm can be considered adequate
in BCC excision. This minimum margin may be considered
for some particular areas as nose, eyelid, and lips, for a better
functional and aesthetic result (Figures 1(a), 1(b), 2(a), 2(b),
3(a), 3(b)).
In back- to legs- areas, a margin of excision ranging from
0.5 cm and 1 cm can be used, creating no significant changes
in function and aesthetic and ensuring complete clearance.
According to Smeets et al. [9], the overall 5-year
recurrence rate is 4,5%, using the Mohs surgery against a
recurrence rate of 3.96% with a peripheral margin of 3mm.
These results highlights that although aesthetic results using
Mohs technique are very good, from an oncological radicality
standpoint Mohs technique is inferior to classical excision.
5. Conclusions
This paper focuses on how evaluation and standardization of
excisional margins is a priority for a correct surgical activity.
4 Journal of Skin Cancer
(a) (b)
Figure 3: (a) and (b) Pre-post operative on lower eye-lid.
An excisional margin >4mm should be ensured in facial
area and a margin >6mm in other body areas. Only on
rare occasions, excision can be performed with a peripheral
margin of 3mm. Then, a differentiation on excisional
margins based on the location of the lesion should be made
to ensure the best result from an oncological, functional, and
aesthetic standpoint.
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